此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估 Crovalimab 在非典型溶血性尿毒症综合征 (aHUS) 儿科参与者中的疗效、安全性、药代动力学和药效学的研究 (COMMUTE-p)

2026年9月30日 更新者:Hoffmann-La Roche

一项评估 Crovalimab 在非典型溶血性尿毒症综合征 (aHUS) 儿科患者中的疗效、安全性、药代动力学和药效学的 III 期、多中心、单臂研究

This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

研究概览

地位

主动,不招人

干预/治疗

研究类型

介入性

注册 (实际的)

41

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100034
        • Peking University First Hospital
      • Beijing、中国、100045
        • Beijing Children's Hospital, Capital Medical University
      • Hangzhou、中国、310051
        • The children's hospital , Zhejiang university school of medicine
    • Quebec
      • Montreal、Quebec、加拿大、H3T 1C5
        • CHU Sainte-Justine
    • Gujarat
      • Ahmedabad、Gujarat、印度、380016
        • Institute of Kidney Diseases and Research Centre
    • Haryana
      • Gurgaon、Haryana、印度、122001
        • Medanta-The Medicity
    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、印度、110029
        • All India Institute Of Medical Sciences (AIIMS)
      • Zapopan、墨西哥、45116
        • Hospital de Especialidades Puerta de Hierro S.A de C.V.
    • São Paulo
      • São Paulo、São Paulo、巴西、05403-900
        • Inst. Da Criança- Faculdade de Medicina Usp
      • Aichi、日本、474-8710
        • Aichi Children?s Health and Medical Center
      • Chibashi, Chibaken、日本、266-0007
        • Chiba Children's Hospital
      • Ghent、比利时、9000
        • UZ Gent
      • Leuven、比利时、3000
        • UZ Leuven Gasthuisberg
      • Montpellier、法国、34295
        • Hôpital Arnaud de Villeneuve
      • Paris、法国、75743
        • Gh Necker Enfants Malades
      • Gdansk、波兰、80-294
        • Uniwersyteckie Centrum Kliniczne
      • Lodz、波兰、93-338
        • Instytut ?Centrum Zdrowia Matki Polki
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital Colorado
    • Nebraska
      • Omaha、Nebraska、美国、68198
        • University of Nebraska
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • Hackensack University Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

4周 至 17年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Body weight >= 5 kg at screening.
  • Vaccination against Neisseria meningitis serotypes A, C, W, and Y; vaccination against serotype B, according to national vaccination recommendations.
  • Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
  • For patients continuing to receive other therapies concomitantly with crovalimab (e.g., immunosuppressants, corticosteroids, mammalian target of rapamycin inhibitor (mTORi), or calcineurin inhibitors): stable dose for >=28 days prior to screening and up to the first crovalimab administration.
  • For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
  • Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
  • Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
  • Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
  • Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
  • Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP participants in the Pretreated Cohort only).
  • Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only).

Exclusion Criteria:

  • TMA associated with non-aHUS related renal disease.
  • Positive direct Coombs test.
  • Chronic dialysis within 90 days prior to first crovalimab administration , and /or end stage renal disease
  • Identified drug exposure-related TMA.
  • Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease.
  • History of a kidney disease, other than aHUS.
  • History of Neisseria meningitidis infection within 6 months of study enrollment.
  • Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
  • Positive HIV test.
  • Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration.
  • Presence of fever (>= 38°C) before the first crovalimab administration (If fevers are solely due to the underlying aHUS pathology, and there is no evidence or suspicion of a systemic infection, participants may enroll).
  • Multi-system organ dysfunction or failure.
  • Recent intravenous immunoglobulin (IVIg) treatment.
  • Pregnant or breastfeeding or intending to become pregnant.
  • Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
  • Recent use of tranexamic acid.
  • Current or previous treatment with a complement inhibitor (for Naive Cohort only).
  • First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only).
  • Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Cohort only).
  • Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
  • Normalization of serum creatinine values at baseline (<97.5th percentile for age), (for Naive Cohort only).
  • Positive for active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor treatment).
  • Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
  • Diagnosis of a condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect (as demonstrated by either increased total blood homocysteine levels or MMACHC gene mutation) and TMA related to Diacylglycerol kinase ε (DGKE) nephropathy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Crovalimab

Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.

Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing => 40 to <100 kg) or 1500 mg IV (for participants weighing >=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing => 40 to <100 kg) or 1020 mg SC (for participants weighing >=100 kg). Enrollment of participants weighing <40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing >=20 kg to <40 kg, followed by Group 2 participants weighing >=5 kg to <20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Naïve Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 (After 24 Weeks on Treatment)
大体时间:From baseline up to Week 25

cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ lower limit of normal (LLN); Lactate dehydrogenase (LDH) ≤ upper limit of normal (ULN); and ≥ 25% decrease in serum creatinine from baseline. Participants with normalized creatinine (i.e., LLN ≤ creatinine ≤ ULN) at baseline were excluded from analysis. 95% confidence interval (CI) was calculated using Wilson's score method. Percentage has been rounded off.

From baseline up to Week 25

次要结果测量

结果测量
措施说明
大体时间
Naïve and Switch Cohorts: Observed Value of Platelet Count
大体时间:Baseline and Week 25
Baseline and Week 25
Naïve and Switch Cohorts: Observed Value of LDH
大体时间:Baseline and Week 25
Baseline and Week 25
Naïve and Switch Cohorts: Observed Value of Hemoglobin (Hb)
大体时间:Baseline and Week 25
Baseline and Week 25
Naïve and Switch Cohorts: Change From Baseline to Week 25 (After 24 Weeks on Treatment) in Platelet Count
大体时间:Baseline and Week 25
Baseline and Week 25
Naïve and Switch Cohorts: Change From Baseline to Week 25 (After 24 Weeks on Treatment) in LDH
大体时间:Baseline and Week 25
Baseline and Week 25
Naïve and Switch Cohorts: Change From Baseline to Week 25 (After 24 Weeks on Treatment) in Hb
大体时间:Baseline and Week 25
Baseline and Week 25
All Cohorts: Serum Concentrations of Crovalimab Over Time
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Observed Value of Total Complement Activity 50 (CH50), as Measured by Liposome Immunoassay (LIA)
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIA
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated Participants
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated Participants
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated Participants
大体时间:Up to approximately 8 years
Up to approximately 8 years
All Cohorts: Change From Baseline in Total C5 Concentrations Over Time in Crovalimab-treated Participants
大体时间:Up to approximately 8 years
Up to approximately 8 years
Naïve and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline or Week 25 and Who Completed 24 Weeks of Treatment
大体时间:Baseline and Week 25

Participants were considered to be on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. The percentage of participants who required dialysis at baseline and Week 25 has been reported here. Percentages have been rounded off.

Baseline and Week 25
Naïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)
大体时间:From baseline up to Week 25

Participants were considered as being on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. Percentages have been rounded off.

From baseline up to Week 25
Naïve and Switch Cohorts: Observed Value of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum Creatinine
大体时间:Baseline, Weeks 2, 3, 4, 5, 7, 9, 11, 13, 17, 21, and 25

GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to chronic kidney disease (CKD) staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation. eGFR (milliliters per minute per 1.73 square meter [mL/min/1.73 m^2])=0.413*(height [ht]/serum creatinine [sCr]), if height is expressed in centimeters, or 41.3*(ht/sCr), if height is expressed in meters.

Baseline, Weeks 2, 3, 4, 5, 7, 9, 11, 13, 17, 21, and 25
Naïve and Switch Cohorts: Change From Baseline to Week 25 in eGFR, as Calculated From Central Serum Creatinine
大体时间:Baseline, Weeks 2, 3, 4, 5, 7, 9, 11, 13, 17, 21, and 25

GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to CKD staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation. eGFR (mL/min/1.73 m^2])=0.413*(ht/sCr), if height is expressed in centimeters, or 41.3*(ht/sCr), if height is expressed in meters.

Baseline, Weeks 2, 3, 4, 5, 7, 9, 11, 13, 17, 21, and 25
Naïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) in CKD Stage, as Assessed Based on eGFR Calculated From Central Serum Creatinine
大体时间:From baseline up to Week 25

CKD stage was assessed using eGFR, calculated from central serum creatinine using Creatinine-based bedside Schwartz equation & classified according to National Kidney Foundation CKD staging criteria as follows: G1 (≥90 mL/min/1.73 m²; normal or high kidney function), G2 (60-89 mL/min/1.73 m²; mildly decreased kidney function), G3a (45-59 mL/min/1.73 m²; mildly to moderately decreased kidney function), G3b (30-44 mL/min/1.73 m²; moderately to severely decreased kidney function), G4 (15-29 mL/min/1.73 m²; severely decreased kidney function), & G5 (<15 mL/min/1.73 m²; kidney failure). Change in CKD stage from baseline to Week 25 was categorized as improved (participants who improved in CKD stage from Baseline to Week 25 were based on the number of participants who completed 24 weeks and were not Stage 1 at baseline), stable (no change), or worsened (participants with CKD Stage 1 to 4 at baseline) among participants who completed 24 weeks of treatment. Percentages have been rounded off.

From baseline up to Week 25
Naïve Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
大体时间:From baseline up to Week 25

This event was confirmed at two separate assessments obtained at least 4 weeks (a minimum of 26 days) apart and any measurement in between.

From baseline up to Week 25
Naïve Cohort: Percentage of Participants With LDH Normalization (i.e., ≤ ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
大体时间:From baseline up to Week 25

Percentage has been rounded off.

From baseline up to Week 25
Naïve Cohort: Percentage of Participants With ≥ 25% Decrease in Serum Creatinine From Baseline, Confirmed at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
大体时间:From baseline up to Week 25

Percentage has been rounded off.

From baseline up to Week 25
Naïve Cohort: Time to cTMAr
大体时间:From baseline up to Week 25

cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline. Kalpan-Meier (K-M) method was used to estimate median time to cTMAr. Data for participants who did not reach cTMAr during PTP were censored at the date of their last visit when cTMAr was assessed during the primary treatment period or prior to the treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy during the PTP were censored at the date of the first received prohibited therapy during the primary treatment period or prior to the treatment discontinuation, whichever was earlier.

From baseline up to Week 25
Naïve Cohort: Duration of cTMAr, Among Participants Who Achieved cTMAr
大体时间:From baseline up to primary CCOD (up to 190 weeks)

cTMAr=meeting following criteria at 2 separate assessments, obtained at least 4 weeks (minimum of 26 days) apart & any measurement in between: Platelet count ≥LLN; LDH ≤ULN; & ≥25% decrease in serum creatinine from baseline. Duration of cTMAr was calculated as time from start of cTMAr to end of cTMAr. End of cTMAr=when all of following criteria were met during same visit & confirmed at assessment that took place at least 4 weeks (minimum of 26 days) later: Platelet count <LLN; LDH >ULN; & ≥25% increase in serum creatinine from baseline & ULN. K-M method was used to estimate the median duration of cTMAr. Data for participants with no observed end of cTMAr at CCOD were censored at the date of their last visit when cTMAr was assessed before CCOD or before treatment discontinuation, whichever was earlier. Data for participants who received prohibited therapy before CCOD were censored at date of first receiving prohibited therapy or before treatment discontinuation, whichever was earlier.

From baseline up to primary CCOD (up to 190 weeks)
Naïve Cohort: Percentage of Participants With cTMAr Ongoing at Week 25
大体时间:At Week 25

cTMAr at Week 25 was defined by meeting all of the three cTMAr criteria at Week 25: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline. Percentage has been rounded off.

At Week 25
Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Response Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)
大体时间:From baseline up to Week 25

mTMAc was considered not maintained if all of the following criteria were met during one of the visits between baseline and Week 25, and were confirmed at an assessment that took place at least 4 weeks (a minimum of 26 days) later: Platelet count < LLN; LDH > ULN; and 25% increase in serum creatinine from baseline.

From baseline up to Week 25
All Cohorts: Number of Participants With Adverse Events (AEs)
大体时间:Up to approximately 8 years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 8 years
All Cohorts: Number of Participants With Injection-site Reactions, Infusion-related Reactions, Hypersensitivity, Malignant Hypertension (Including Malignant Renal Hypertension), and Infections (Including Meningococcal Meningitis)
大体时间:Up to approximately 8 years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 8 years
All Cohorts: Number of Participants With AEs Leading to Study Drug Discontinuation
大体时间:Up to approximately 8 years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 8 years
Switch Cohort: Number of Participants With Clinical Manifestations of Drug-target-drug Complexes (DTDCs)
大体时间:Up to approximately 8 years

Crovalimab and eculizumab bind distinct epitopes on complement component C5, and formation of DTDCs comprising crovalimab, eculizumab, and C5 are formed when participants switch treatment. DTDCs will be characterized using size exclusion chromatography (SEC) coupled with enzyme-linked immunosorbent assay (ELISA).

Up to approximately 8 years
All Cohorts: Number of Participants With Anti-drug Antibodies (ADAs) to Crovalimab
大体时间:Up to approximately 8 years

Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following stuy drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).

Up to approximately 8 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trials、Hoffmann-La Roche

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年11月17日

初级完成 (实际的)

2025年7月4日

研究完成 (估计的)

2029年5月19日

研究注册日期

首次提交

2021年7月6日

首先提交符合 QC 标准的

2021年7月6日

首次发布 (实际的)

2021年7月12日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅